China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a feature story on contract research organizations in China. Part one highlighted the evolution of the CRO industry, which has grown and changed to reflect the needs of both local and multinational pharma companies, which are increasingly outsourcing R&D projects to China. ]
You may also be interested in...
Pharmaron Acquires Bridge China To Become Fully-integrated CRO
SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio
Pharmaron Acquires Bridge China To Become Fully-integrated CRO
SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio
China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 1 of 2)
SHANGHAI - By the end of 2009 there were roughly 500 contract research organizations in China, most of which are small registration consultants, and about 150 execute research work. Driven by the trend to offshore R&D work from big pharmas and the double digital growth of the Chinese market, the number of CRO companies is expected to increase further and offer broader services in the upcoming Chinese Year of The Tiger